SMAD4 and echinococcosis: This discovery not only reveals the central pathogenic driver role of the SUMO-Smad4 axis in parasite-induced fibrogenesis, but also provides a novel therapeutic target and candidate drug for anti-fibrotic treatment in hepatic echinococcosis.